DK2575768T3 - Aqueous Dispersion Comprehensive Galactolipids and Procedures for their Preparation - Google Patents
Aqueous Dispersion Comprehensive Galactolipids and Procedures for their Preparation Download PDFInfo
- Publication number
- DK2575768T3 DK2575768T3 DK11786992.5T DK11786992T DK2575768T3 DK 2575768 T3 DK2575768 T3 DK 2575768T3 DK 11786992 T DK11786992 T DK 11786992T DK 2575768 T3 DK2575768 T3 DK 2575768T3
- Authority
- DK
- Denmark
- Prior art keywords
- ethanol
- oil
- water
- polar lipids
- lipids
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 147
- 239000006185 dispersion Substances 0.000 title claims description 127
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 443
- 150000002632 lipids Chemical class 0.000 claims description 290
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 139
- 239000000203 mixture Substances 0.000 claims description 121
- 239000002245 particle Substances 0.000 claims description 116
- 230000008569 process Effects 0.000 claims description 83
- 239000002904 solvent Substances 0.000 claims description 68
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 65
- 238000010790 dilution Methods 0.000 claims description 56
- 239000012895 dilution Substances 0.000 claims description 56
- 239000002502 liposome Substances 0.000 claims description 56
- 235000007319 Avena orientalis Nutrition 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 45
- 235000013305 food Nutrition 0.000 claims description 23
- 238000001246 colloidal dispersion Methods 0.000 claims description 17
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 238000001704 evaporation Methods 0.000 claims description 14
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000008961 swelling Effects 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002269 spontaneous effect Effects 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 4
- 150000002888 oleic acid derivatives Chemical class 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 238000000386 microscopy Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- 241000209761 Avena Species 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- 239000012071 phase Substances 0.000 description 184
- 239000003921 oil Substances 0.000 description 110
- 235000019198 oils Nutrition 0.000 description 108
- 244000075850 Avena orientalis Species 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 35
- 239000000047 product Substances 0.000 description 29
- 208000008589 Obesity Diseases 0.000 description 27
- 235000020824 obesity Nutrition 0.000 description 27
- 239000007787 solid Substances 0.000 description 25
- 238000009826 distribution Methods 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 239000000306 component Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000036186 satiety Effects 0.000 description 16
- 235000019627 satiety Nutrition 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 239000002691 unilamellar liposome Substances 0.000 description 13
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 238000010587 phase diagram Methods 0.000 description 11
- 230000001804 emulsifying effect Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 9
- 239000012467 final product Substances 0.000 description 9
- 241000209140 Triticum Species 0.000 description 8
- 235000021307 Triticum Nutrition 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 229940074096 monoolein Drugs 0.000 description 8
- 238000010923 batch production Methods 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 7
- 150000002149 estolides Chemical class 0.000 description 7
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 7
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000003113 dilution method Methods 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000001586 synchrotron small angle X-ray scattering Methods 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 206010053317 Hydrophobia Diseases 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 229940086609 Lipase inhibitor Drugs 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 244000027321 Lychnis chalcedonica Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005428 food component Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 206010041969 Steatorrhoea Diseases 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000004464 cereal grain Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical group C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000007863 gel particle Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000001162 steatorrhea Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- ZXSWTMLNIIZPET-ZOFHRBRSSA-N Normethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000004990 Smectic liquid crystal Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003608 autoimmunological effect Effects 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019869 fractionated palm oil Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- -1 vesicles Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34764310P | 2010-05-24 | 2010-05-24 | |
| SE1050515 | 2010-05-24 | ||
| PCT/SE2011/050646 WO2011149416A1 (en) | 2010-05-24 | 2011-05-24 | Aqueous dispersion comprising galactolipids and method for production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2575768T3 true DK2575768T3 (en) | 2018-03-12 |
Family
ID=45004194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11786992.5T DK2575768T3 (en) | 2010-05-24 | 2011-05-24 | Aqueous Dispersion Comprehensive Galactolipids and Procedures for their Preparation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9237762B2 (https=) |
| EP (1) | EP2575768B1 (https=) |
| DK (1) | DK2575768T3 (https=) |
| ES (1) | ES2662710T3 (https=) |
| NO (1) | NO2575768T3 (https=) |
| PL (1) | PL2575768T3 (https=) |
| WO (1) | WO2011149416A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019005830A1 (en) * | 2017-06-26 | 2019-01-03 | Fordoz Pharma Corp. | NANOSOME FORMULATIONS OF APREPITANT AND METHODS AND APPLICATIONS THEREOF |
| WO2021077061A1 (en) * | 2019-10-18 | 2021-04-22 | Quicksilver Scientific, Inc. | Self-microemulsifying multi-deliverable systems |
| GB201916585D0 (en) * | 2019-11-14 | 2020-01-01 | Givaudan Sa | Concentrate |
| WO2025133121A2 (en) * | 2023-12-21 | 2025-06-26 | Emulsi Biotech Ab | Compositions and methods of making them |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| SE8505569D0 (sv) | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | Enteralt preparat |
| CA2182577C (en) * | 1994-02-04 | 2002-08-20 | Anders Carlsson | Lipophilic carrier preparations |
| WO1995020943A1 (en) * | 1994-02-04 | 1995-08-10 | Scotia Lipidteknik Ab | Oil-in-water emulsions |
| CN1083713C (zh) * | 1994-02-04 | 2002-05-01 | 利珀克尔集团公司 | 双层制剂 |
| JPH10508322A (ja) | 1995-10-12 | 1998-08-18 | スーパーゲン，インコーポレイティド | ５βステロイドのリポソーム配合物 |
| SE9702630D0 (sv) | 1997-07-07 | 1997-07-07 | Scotia Lipidteknik Ab | Satiety product |
| US6123959A (en) * | 1998-04-24 | 2000-09-26 | Univera Pharmaceuticals, Inc. | Aqueous composition comprising active ingredients for the de-pigmentation of the skin |
| AR022204A1 (es) | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
| US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
| US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| WO2003018529A1 (en) | 2001-08-24 | 2003-03-06 | Girouard Michael P | Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents |
| EP1817078A1 (en) | 2004-11-16 | 2007-08-15 | Unilever N.V. | Satiety emulsions and food compositions |
| MX2007013411A (es) | 2005-05-04 | 2008-01-15 | Unilever Nv | Emulsiones de saciedad y composiciones alimenticias. |
| CA2609208C (en) | 2005-06-10 | 2016-10-18 | Per-Ake Albertsson | Use of plant cell membrane for the treatment of obesity |
| PL1919450T3 (pl) * | 2005-09-01 | 2014-11-28 | Meda Ab | Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych |
| WO2007075142A1 (en) | 2005-12-24 | 2007-07-05 | Dsm Ip Assets B.V. | Long term weight maintenance |
| EP3219307B1 (en) * | 2005-12-30 | 2021-09-08 | NuVessl Inc. | Nanolipidic particles |
| JP2007204368A (ja) | 2006-01-30 | 2007-08-16 | Sunstar Inc | 絹ペプチドを有効成分とするＮＦ−κＢ活性阻害剤及び経口組成物 |
| WO2009031436A1 (ja) | 2007-09-03 | 2009-03-12 | Dai Nippon Printing Co., Ltd. | 包装体とその製造方法及び装置 |
| WO2009068651A1 (en) * | 2007-11-28 | 2009-06-04 | Dsm Ip Assets B.V. | Lipid emulsion for human consumption |
| WO2009068661A1 (en) | 2007-11-29 | 2009-06-04 | Universiteit Maastricht | Device for thoracostomy |
| WO2009131436A1 (en) * | 2008-04-25 | 2009-10-29 | Campina Nederland Holding B.V. | Drinking yoghurt |
| CN101632637B (zh) * | 2008-07-22 | 2011-04-27 | 清华大学 | 一种多烯紫杉醇脂质制剂及其制备方法 |
-
2011
- 2011-05-24 NO NO11786992A patent/NO2575768T3/no unknown
- 2011-05-24 DK DK11786992.5T patent/DK2575768T3/en active
- 2011-05-24 EP EP11786992.5A patent/EP2575768B1/en active Active
- 2011-05-24 ES ES11786992.5T patent/ES2662710T3/es active Active
- 2011-05-24 US US13/699,663 patent/US9237762B2/en active Active
- 2011-05-24 WO PCT/SE2011/050646 patent/WO2011149416A1/en not_active Ceased
- 2011-05-24 PL PL11786992T patent/PL2575768T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2575768T3 (pl) | 2018-07-31 |
| WO2011149416A1 (en) | 2011-12-01 |
| NO2575768T3 (https=) | 2018-05-12 |
| US20130129801A1 (en) | 2013-05-23 |
| EP2575768A1 (en) | 2013-04-10 |
| ES2662710T3 (es) | 2018-04-09 |
| US9237762B2 (en) | 2016-01-19 |
| EP2575768A4 (en) | 2014-07-02 |
| EP2575768B1 (en) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ashaolu | Nanoemulsions for health, food, and cosmetics: a review | |
| Choi et al. | Nanoemulsions as delivery systems for lipophilic nutraceuticals: strategies for improving their formulation, stability, functionality and bioavailability: SJ Choi, DJ McClements | |
| McClements et al. | Enhancing nutraceutical performance using excipient foods: Designing food structures and compositions to increase bioavailability | |
| Zou et al. | Utilizing food matrix effects to enhance nutraceutical bioavailability: increase of curcumin bioaccessibility using excipient emulsions | |
| McClements et al. | Boosting the bioavailability of hydrophobic nutrients, vitamins, and nutraceuticals in natural products using excipient emulsions | |
| Tan et al. | Modulation of the carotenoid bioaccessibility through liposomal encapsulation | |
| Lv et al. | Vitamin E encapsulation in plant-based nanoemulsions fabricated using dual-channel microfluidization: Formation, stability, and bioaccessibility | |
| DK2548456T3 (en) | Emulsions including (comprising) a PEG derivative of tocopherol | |
| AU2007212412B2 (en) | Dietary supplement composition for blood lipid health | |
| Roohinejad et al. | Emulsion-based systems for delivery of food active compounds: formation, application, health and safety | |
| Fatouros et al. | Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products | |
| MX2010010214A (es) | Derivados de vitamina e y sus usos. | |
| Sadeghpour et al. | Bile salts caught in the act: from emulsification to nanostructural reorganization of lipid self-assemblies | |
| JP2016128425A (ja) | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 | |
| JP2019205456A (ja) | 可食無機塩の粒子によって安定化されたエマルション | |
| CN107744024A (zh) | 亲水性的脂类组合物，其制备及调配方法和应用 | |
| Lin et al. | In vitro–in vivo study of the impact of excipient emulsions on the bioavailability and antioxidant activity of flavonoids: Influence of the carrier oil type | |
| DK2575768T3 (en) | Aqueous Dispersion Comprehensive Galactolipids and Procedures for their Preparation | |
| Mangrulkar et al. | A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin | |
| JP2004534793A (ja) | 安定化されたフィトステロールの油中分散液 | |
| EP3129003A1 (en) | Food matrices and methods of making and using | |
| Liang et al. | Improving the physicochemical stability of soy phospholipid-stabilized emulsions loaded with lutein by the addition of sphingomyelin and cholesterol: Inspired by a milk fat globule membrane | |
| Engström et al. | Microemulsions in foods | |
| US20240307474A1 (en) | Fermented Uni-sourced Nanoemulsion of Nigella sativa or Cannabis sativa For Use in Medical, Cosmetic, and Recreational Indications with a Method of Its Production and Use | |
| Kaur | Nanoemulsions as delivery vehicles for food and pharmaceuticals |